Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Noble Life Sciences Partners with BioFactura

Published: Friday, July 27, 2012
Last Updated: Friday, July 27, 2012
Bookmark and Share
Partnership to offer cell line development and preclinical protein production services.

Noble Life Sciences, Inc. has announced a partnership with BioFactura, Inc. (Rockville, MD), a developer and provider of proprietary technologies and services for production of biological.

The collaboration expands Noble’s CRO services to include the development and production of monoclonal antibody and other protein-based drugs.

Through the partnership, Noble becomes the exclusive commercial contract services provider of BioFactura’s technologies and capabilities.

BioFactura’s capabilities enable rapid, scalable, high potency production of protein drug candidates in mammalian and microbial systems, from development of expression vectors and cell lines to growth medium optimization, protein purification, and process scale-up.

BioFactura’s StableFast™ biomanufacturing platform is a unique, patented system for developing stable mammalian NS0 cell lines that can generate over one gram of protein in eight weeks.

“This relationship allows Noble to offer end-to-end preclinical biopharmaceutical development services - from cell line development to protein production, in vitro screening, in vivo efficacy and pharmacodynamics testing and biomarker development” said Alain Cappeluti, Noble Life Sciences President.

“We are looking forward to working with Noble to provide drug developers wider access to our unique capabilities,” said Darryl Sampey, BioFactura’s President and CEO.

Sampey continued, “This partnership creates an excellent synergy between Noble’s experienced scientific drug development team and BioFactura’s protein bioprocessing expertise.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Noble Life Sciences Receives Maryland TEDCO Award
Licenses Vitatex patents for enrichment of invasive circulating tumor cells.
Friday, December 06, 2013
Scientific News
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!